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abstRact
IntroductIon: Using multidetector computed tomogra­
phy, we aimed to assess the early response of neoadjuvant 
drug therapy for locally advanced colon cancer. 
Methods: Computed tomography with IV contrast was ac­
quired from 67 patients before and after up to three cycles 
of preoperative treatment. All patients had histologically 
confirmed colon cancer, a T4 or T3 tumour with extramural 
invasion ≥ 5 mm and no distant metastases or peritoneal 
nodules. The patients were treated with oxaliplatin and 
capecitabine. In addition, those with no mutations in the 
KRAS, BRAF and PIK3CA genes were also treated with pan­
itumumab.  Before and after treatment, we measured the 
tumour diameter in two different planes, the extension of 
the extramural tumour invasion, and the number and size 
of enlarged lymph nodes. 
results: The mean tumour length was 7.8 cm (95% confi­
dence interval (CI): 5.3-10.4) at baseline and 4.34 cm (95% 
CI: 4.0-4.9) after treatment. The mean extramural tumour 
invasion was 10.6 mm (95% CI: 9.5-11.8) at baseline and 5.7 
mm (95% CI: 4.7-6.7) after treatment. The mean number of 
enlarged lymph nodes was 4.1 (95% CI: 3.4-4.9) at baseline 
and 2.1 (95% CI: 1.4-2.7) after treatment. According to RE­
CIST 1.1, 45% (95% CI: 34-57) of the patients had a response 
and 55% (95% CI: 43-67) had stable disease. None of the pa­
tients showed progressive disease. 
conclusIon: Using CT, we demonstrated a significant re­
duction in tumour size, extramural tumour invasion, num­
ber and size of enlarged lymph nodes following neoadju­
vant treatment. 
FundIng: not relevant. 
trIal regIstratIon: Registered with ClinicalTrials.gov 
(NCT 01108107).
Colorectal cancer is the second most common type of 
cancer in the developed countries, and it is associated 
with significant morbidity and mortality. Previously, the 
treatment was surgery alone, but about half of the re­
sected patients developed incurable recurrent disease. 
Post­operative adjuvant chemotherapy is now well es­
tablished and represents a moderate improvement in 
survival for some patients with stage II and III colorectal 
cancer [1]. Neoadjuvant chemotherapy (NEC) has been 
shown to be effective in a number of locally advanced 
gastrointestinal cancers, including rectal cancer, and is 
presumed to have potential for improving the outcome 
in colon cancer [2, 3]. 
Combination chemotherapy regimens such as 
capecitabine plus oxaliplatin are established as treat­
ment in advanced colorectal cancer; and in some pa­
tients. higher response rates can be achieved by adding 
epidermal growth factor receptor (EGFR) targeted ther-
apies [4] It is well known that Kirsten rat sarcoma viral 
oncogene homologue (KRAS) mutation predicts the re­
sponse to targeted EGFR therapy [5] An enhanced re­
sponse is observed in patients with KRAS­wild type (nor­
mal) tumours, but no benefit is seen in KRAS­mutant 
tumours. Therapeutic inhibition of EGFR can be achieved 
with monoclonal antibodies such as panitumumab which 
has been proven to be useful in colorectal cancer [6].
Multidetector computed tomography (MDCT) is 
currently the standard modality for classification of co­
lon cancer before curative surgical therapy [7]. MDCT 
colon has a low accuracy in determining the correct tu­
mour (T) and necrosis (N) stage of colonic cancer and a 
reasonable accuracy only for identifying patients with 
advanced (T3/T4) colon cancer [3, 8]. 
Assessment of tumour response by CT in locally ad­
vanced gastric cancer following NEC has been made [9]; 
but to best of our knowledge, there are no finalised, 
large, systematic studies of colon cancer demonstrating 
the early effect of NEC using CT. The aim of the present 
study was to assess the early effect of NEC in locally ad­
vanced colon cancer by means of MDCT. 
mEthOds
This study formed part of the prospective multicentre 
study: “Neoadjuvant Chemotherapy and Biological 
Treatment for Patients with Locally Advanced Colon 
Cancer” performed in the Departments of Oncology, Ra­
diology, and Clinical Pathology, Vejle, Herlev and Hille­
roed Hospitals in Denmark [10]. The multicentre study 
was approved by the Regional Scientific Ethical Commit­
tee for Southern Denmark (S-20100014) and registered 
at ClinicalTrials.gov (NCT 01108107). 
The inclusion criteria were histologically verified co­
lon cancer, CT­verified  T4 or T3 tumour with extramural 
tumour invasion (ETI) ≥ 5 mm, absence of distant metas­
tases and peritoneal nodules as assessed by CT, analysis 
of KRAS, BRAF, PIK3CA, age over 18 years, performance 
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status 0-2, absolute neutrophil count (ANC) ≥ 1.5 × 109/l 
and thrombocytes ≥ 100 × 109/l, bilirubin ≤ 3 × upper 
normal limit (UNL) and alanine aminotransferase (ALAT) 
≤ 5 × UNL, consent to translational research, a negative 
pregnancy test in fertile women and use of secure birth 
control during and three months after treatment, and 
written and orally informed consent. The exclusion cri­
teria were clinically significant cardiovascular disease 
(including myocardial infarction, unstable angina, symp­
tomatic congestive heart failure, serious uncontrolled 
cardiac arrhythmia) ≤ 1 year before enrolment, active 
severe infections or other concurrent disease, peripheral 
neuropathy National Cancer Institute (NCI) grade > 1, 
other malignant disease within five years prior to enrol­
ment except basal cell squamous carcinoma of the skin 
and cervical carcinoma in­situ, other investigational 
treatment within 30 days prior to treatment start, his-
tory of interstitial lung disease, e.g. pneumonitis or pul­
monary fibrosis or evidence of interstitial lung disease 
on the baseline chest CT, bleeding tumours, and hyper­
sensitivity to one or more of the substances of the study 
treatment. 
The neoadjuvant chemotherapy was initialised ≤ 2 
weeks after the baseline CT. Patients with gene muta­
tions were treated with three cycles of oxaliplatin 130 
mg/m2 intravenously (IV) on day 1 of a three-week cycle 
and oral capecitabine 2,000 mg/m2/day on days 1-14 of 
a three-week cycle. Additionally, patients without gene 
mutations were treated with panitumumab 9 mg/kg IV 
on day 1 of a three-week cycle.
Three weeks after NEC, 67 of 71 patients had an 
MDCT scan with IV contrast just prior to operation. Four 
patients were excluded as their CT after NEC was not 
performed, either due to lack of request or lacking pa­
tient compliance (Figure 1). Philips Brilliance 64­slice CT 
scanners (Philips, Eindhoven, The Netherlands) with 
Dynamic Dose Modulation were used. The CT was per­
formed with a breath­hold technique in portal phase 
with IV contrast 100 ml iomeprol (Iomeron, Bracco, 
FigURE 1
Patient pathway.
77 patients with locally
advanced colonic 
tumours included
6 excluded: ileus, renal disease, withdrew
content, protocol violation, distant
metastases, non-resectable tumour
71 operated
4 patients had only 1 CT performed
Study population:
67 patients
CT = computed tomography.
FigURE 2
a. Axial multidetector 
computed tomography 
(MDCT) slides shows 
right­sided T3 colon tu­
mour with > 5 mm extra­
mural invasion (top) and 
the reduction of tumour 
size and extramural tu­
mour invasion after neo­
adjuvant therapy (bot­
tom). b. Axial MDCT 
slides shows sigmoid T3 
colon tumour with > 5 
mm extramural invasion 
(top) and the reduction of 
tumour size and extra­
mural tumour invasion  
after neoadjuvant therapy 
(bottom).
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Milan, Italy) 300 mg I/ml using an automatic injector 
OptiVantag DH (Mallinckrodt, Cincinnati, Ohio, USA) 
with an injection rate of 4 ml/sec. 
The baseline and post-NEC images from 3-mm CT 
slices underwent central review by an experienced gas­
trointestinal radiologist (over ten years of experience) 
with at least one week between the reviews. The radi-
ologist was blinded from the baseline MDCT and the re­
ports during the evaluation of the post-NEC scan. The  
radiologist assessed axial tumour diameter, largest tu­
mour diameter (length) in a reconstructed plane, exten­
sion of ETI, number of enlarged lymph nodes (> 5 mm), 
length and width of the largest regional lymph node us­
ing an Easy Viz PACS workstation (Medical Insight, Valby, 
Denmark) with a Coronis monitor (1,600 × 1,200 pixels), 
Megapixels Diagnostic Display System (Barco, Kortijk, 
Belgium). Multiplanar reconstruction was performed on 
the picture archiving and communication system (PACS). 
The response was evaluated according to the guidelines 
of the revised Response Evaluation Criteria in Solid Tu-
mors (RECIST 1.1) [11].
Statistical analysis was performed using Number 
Cruncher Statistical Systems (NCSS, Kaysville, Utah, 
USA). Confidence limits were set at 95%. Descriptive 
stat istics was used. The H0 hypothesis was that there 
was no difference between the MDCT prior to and after 
NEC. Significance in change of the different parameters 
before and after NEC was calculated using the Wilcoxon 
signed-rank sum test. p-values < 0.05 were considered 
significant.
Trial registration: registered with ClinicalTrials.gov (NCT 
01108107).
REsUlts
A total of 37 males and 30 females with a mean age of 
65 years (range: 39-86 years) participated. Generally, 
the preoperative treatment was well tolerated with 90% 
of the patients receiving at least two cycles of chemo­
therapy.
Overall, a reduction in tumour size was observed 
following NEC (Figure 2). The mean values for all 67 pa­
tients are shown in table 1. The extramural tumour in­
vasion of these advanced colonic cancers decreased 
from 11 mm to 6 mm after chemotherapy. The number 
and size of the peritumoral lymph nodes decreased. 
There was a statistically significant reduction in all vari­
ables after NEC compared with baseline (p < 0.001) with 
no overlap of the 95% confidence intervals (CIs). A tu­
mour size reduction was measured in 90% (95% CI: 80-
95%) of the 67 patients, table 2.  As to tumour size ac­
cording to RECIST 1.1, 55% (95% CI: 43.3-66.5) of the 
patients (37 of 67) had stable disease. The two patients 
with tumour growth had an 8% and a 10% increase, re­
spectively. None had progressive disease according to 
RECIST 1.1. 45% (95% CI: 33.5-56.7) of the patients (30 
of 67) responded with a tumour size reduction of > 30%. 
One patient had complete response with no visible tu­
mour after neoadjuvant chemotherapy (Table 2).
discUssiOn
MDCT is the primary tool for preoperative staging of co­
lon cancer. The present study represents an evaluation 
of the effect of NEC. A meta-analysis shows an overall 
sensitivity and specificity in differentiating between  
T1/T2 and T3/T4 tumours of 95% and 50%, respectively. 
When the tumours were stratified according to the clini­
cal distinction between T1/T2 + T3 < 5 mm ETI and T4 + 
T3 ≥ 5 mm ETI, the sensitivity and the specificity of CT in 
identifying poorly prognostic tumours were 87% and 
49%, respectively [12]. With the current 64-slice ma­
chines, it is possible to view reformatted images in three 
dimensions, and a sensitivity and specificity of up to 93% 
and 86%, respectively, in detecting ETI on MDCT com­
pared with histology has been reported [12]. Preliminary 
results from an ongoing study with 48 colon cancer pa­
tients assessed with MDCT by four radiologists and spec­
imen analysis by a single pathologist suggest that MDCT 
is a specific, accurate and reproducible method for iden­
tifying T4 + T3 ≥ 5 mm ETI tumours with a sensitivity of 
tablE 1
Mean values of the measured variables in 67 patients before and after neoadjuvant chemotherapy.
baseline ct,  
mean (95% ci)
Post nEc ct,  
mean (95% ci) p-value
Tumour diameter, cm 4.4 (4.0-4.8) 3.2 (2.8-3.5) < 0.001
Tumour length, cm 7.8 (5.3-10.4) 4.4 (4.0-4.9) < 0.001
Extramural tumour invasion, mm 10.6 (9.5-11.8) 5.7 (4.7-6.7) < 0.001
Pathological lymph nodes, n 4.1 (3.4-4.9) 2.1 (1.4-2.7) < 0.001
Length of largest lymph node, mm 11.0 (9.7-12.2) 7.3 (5.9-8.7) < 0.001
Width of largest lymph node, mm 7.4 (6.5-8.3) 4.9 (4.0-5.7) < 0.001
CI = confidence interval; CT = computed tomography; NEC = neoadjuvant chemotherapy.
tablE 2
Change in tumour diameter in 67 patients after neoadjuvant chemo­
therapy.
REcist 1.1
change in  
tumour diameter Patients, n
Progressive disease Increase: > 20%   0
Stable  disease Increase: 1-20%   2
No change:  0%   5
Decrease: 1-30% 30
Partial response Decrease: > 30% 29
Complete response Disappearance   1
RECIST = Response Evaluation Criteria in Solid Tumors. 
 4  da n i s h m E d i c a l J O U R n a l Dan Med J 62/7  July 2015
64-82%, a specificity of 84-92%, a positive predictive  
value of 50-70%, a negative predictive value of 88-97% 
and an accuracy of MDCT of 75-88%, and the mean 
agreement between observers was 88% (standard devi-
ation: 17%) per patient [13]. There is a potential risk of 
understaging T4 tumours as the detection of, e.g., peri­
toneal microscopical involvement remains a challenge in 
any radiological modality [3]. On the other hand, the 
high accuracy in the clinically significant distinction be­
tween early and advanced colonic cancers makes MDCT 
a relatively safe means of identifying patients suited for 
NEC [8] and for achieving early reduction in tumour size 
and ETI as shown in the present study.
The significant reduction in tumour size, level of ETI, 
and number and size of lymph nodes shown with CT is 
consistent with a recent publication from the FoxTROT 
Collaborative Group [14]. In addition to safety and feasi­
bility, this pilot phase of a multicentre clinical trial 
showed down­staging in 99 locally advanced colon can­
cer patients allocated to NEC when radiological staging 
before preoperative treatment was compared with post­
operative histopathological staging. As to the radiologi­
cal assessment before and after chemotherapy, 11 pa­
tients out of 20 (55%) were truly down-staged and sux 
out of 17 (35%) truly upstaged. A 30% reduction in the 
depth of spread beyond the muscularis propria is con­
sistent with our findings, where the ETI was reduced by 
46%. Another research group also had no patients with 
progressive disease after similar neoadjuvant treatment 
of locally advanced colon cancer [15].
The aim of the present study was to compare MDCT 
before and after treatment to detect the early change in 
ETI and size of tumour and lymph nodes following NEC. 
It is possible that compared with histopathology, the tu­
mour size and the level of ETI were overestimated on 
the post-NEC scan due to fibrotic tissue mimicking viable 
tumour tissue after NEC, as seen after preoperative 
treatment of rectal cancer; but unlike after radiation 
therapy, this is not often seen after chemotherapy [16]. 
The level of ETI has been shown to be one of the main 
independent histological prognostic factors in rectal can­
cer [17]. In the future, additional functional imaging 
such as perfusion CT may also add prognostic informa­
tion and be used for treatment response monitoring in 
these patients [18].  
 The reduction in number and size of pathological 
lymph nodes should be interpreted with caution. CT has 
been shown to have a limitation as far as accurate iden­
tification of malignant nodes is concerned [12]. The 
presence of micro­metastases in normal­sized lymph 
nodes and benign enlargement of inflammatory nodes 
make detection of pathological lymph nodes on CT dubi­
ous. Also, the definition of enlarged lymph nodes on CT 
is not consistent across studies. Magnetic resonance im­
aging with diffusion­weighted imaging may improve the 
detection of lymph nodes in colorectal cancer [19]. 
Other studies have shown fair agreement between 
observers in MDCT interpretation of colon cancer [3, 
20]. The inter-observer accuracy between radiologists in 
our study was not evaluated and this is a limitation. 
However, the experienced gastrointestinal radiologist 
was blinded from the baseline MDCT and reports during 
evaluation of the post-NEC CT, and we introduced a time 
interval between the evaluations of the two scans to re­
duce recall bias. Although blinded from the baseline CT 
results, the reader was not truly blinded because the ra­
diologist knew that the patients were enrolled in the 
study. Another limitation is the exclusion of four pa­
tients due to missing CT three weeks after NEC; how-
ever, these patients were excluded randomly due to 
missing request or lacking patient compliance. 
We have not assessed tumour attenuation response 
to chemotherapy in this study. Tumour response is usu­
ally assessed according to the RECIST criteria based on 
changes in tumour size alone [11]. However, adapted 
Choi criteria incorporating volumetric tumour attenu­
ation in addition to tumour size have been reported to 
be more predictive of the pathologic response than 
RECIST in some studies [9] and might have been useful 
in this study.
In conclusion, using MDCT, we report a significant 
reduction in tumour size, extramural tumour invasion, 
and number and size of pathological regional lymph 
nodes following neoadjuvant treatment of locally ad­
vanced colon cancer. NEC may induce not only tumour 
down­sizing, but may bring about a significant prolonga­
tion of disease­free survival and eventually improve 
overall survival. The shown early response to NEC leads 
to hope for improvement in the outcome of locally ad­
vanced colon cancer patients, and clinical follow­up data 
are warranted.
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